CC2021: Tranexamic Acid in Anterior Cruciate Ligament Reconstruction (December 2021)-CC2021: Tranexamic Acid in Anterior Cruciate Ligament Reconstruction (December 2021)

CC2021: Tranexamic Acid in Anterior Cruciate Ligament Reconstruction (December 2021)

Pdf Summary

Tranexamic acid (TXA) is a drug that is commonly used in adult reconstruction procedures to reduce bleeding. However, its use in ACL reconstruction is a relatively new area of study. In a systematic review and meta-analysis of randomized controlled trials (RCTs), researchers analyzed the available literature on the use of TXA in ACL reconstruction procedures. They found that the use of intravenous TXA in ACL reconstruction surgery resulted in reduced joint drain output and hemarthrosis, improved pain scores and range of motion in the early postoperative period, and did not increase complications or venous thromboembolic events. The analysis included five prospective RCTs that met the inclusion criteria. The studies administered TXA either intravenously or via intra-articular injection before, during, or after ACL reconstruction surgery. The researchers recommended the routine use of intravenous TXA in ACL reconstruction surgery, with a bolus dose administered 10 minutes before tourniquet inflation, and suggested that further study is needed to determine the safety and efficacy of intra-articular TXA in arthroscopic procedures.

Keywords

Tranexamic acid

TXA

ACL reconstruction

reduced bleeding

pain scores

range of motion

complications

RCTs

intravenous TXA

intra-articular injection